Maftivimab

Maftivimab is a monoclonal antibody used in the treatment of Ebola virus disease. It is part of a combination therapy known as REGN-EB3, which also includes the monoclonal antibodies Atoltivimab and Odesivimab. This combination therapy was developed by Regeneron Pharmaceuticals and has shown efficacy in reducing mortality in patients infected with the Ebola virus.

Mechanism of Action

Maftivimab targets the glycoprotein of the Ebola virus, which is essential for the virus's ability to infect host cells. By binding to this glycoprotein, Maftivimab neutralizes the virus, preventing it from entering and replicating within human cells. This action helps to control the spread of the virus within the body and allows the immune system to clear the infection more effectively.

Clinical Trials

Maftivimab, as part of the REGN-EB3 cocktail, was evaluated in the PALM (Pamoja Tulinde Maisha) trial, a randomized controlled trial conducted during the 2018-2020 Ebola outbreak in the Democratic Republic of the Congo. The trial demonstrated that REGN-EB3 significantly reduced mortality compared to the standard of care, leading to its approval for use in treating Ebola virus disease.

Administration and Dosage

Maftivimab is administered intravenously as part of the REGN-EB3 combination. The specific dosage and administration schedule are determined based on the patient's condition and the severity of the infection.

Side Effects

Common side effects of Maftivimab, when used in combination with Atoltivimab and Odesivimab, include infusion-related reactions, such as fever, chills, and rash. Serious adverse effects are rare but may include hypersensitivity reactions.

Regulatory Status

In October 2020, the U.S. Food and Drug Administration (FDA) approved REGN-EB3 for the treatment of Ebola virus disease, marking a significant advancement in the therapeutic options available for this deadly disease.

Also see

• Ebola virus disease
• Monoclonal antibody
• Regeneron Pharmaceuticals
• Atoltivimab
• Odesivimab